Clinical Trials Logo

Clinical Trial Summary

This non-inferiority study aims to determine whether a hydrolysed rice protein formula is as effective as a cow's milk protein based extensively hydrolysed formula using a double-blind, randomised-controlled design over a 28-day intervention period followed by a 2-month follow-up period in infants 0-13 months of age presenting with symptoms/clinical history suggestive of cow's milk allergy. The primary outcome is growth, and secondary outcomes are gastrointestinal tolerance, and differences in intake, allergic symptoms, parental QOL, acceptability, dietary intake, and safety.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06288503
Study type Interventional
Source Nutricia UK Ltd
Contact Isabel Evans, MSc
Phone 07385000738
Email Isabel.EVANS@danone.com
Status Recruiting
Phase N/A
Start date February 1, 2024
Completion date July 2027

See also
  Status Clinical Trial Phase
Completed NCT04596059 - The Journey of Children With Cow's Milk Protein Allergy in Mexico.
Not yet recruiting NCT06130085 - Partially Hydrolyzed Formula in Cow's Milk Protein Allergy After 6 Months of Elimination N/A
Completed NCT03769051 - Study on The Oral Immune Tolerance of CMPA Infants Using Amino Acid Formula
Completed NCT02953223 - A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Completed NCT03085134 - Clinical Safety & Efficacy of a New Infant Formula With Specific Medical Purpose Containing Human Milk Oligosaccharides N/A
Completed NCT06273371 - Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain